• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Synta Pharmaceuticals Corp. (SNTA)

    -NasdaqGM
    2.30 0.00(0.00%) Mar 27, 4:00PM EDT
    |After Hours : 2.30 0.00 (0.00%) Mar 27, 4:33PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Synta Pharmaceuticals Corp.
    45 Hartwell Avenue
    Lexington, MA 02421
    United States - Map
    Phone: 781-274-8200
    Fax: 781-274-8228
    Website: http://www.syntapharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:110

    Business Summary 

    Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; Elesclomol, a mitochondria-targeting agent that is in Phase II clinical trial for ovarian cancer; and CRACM ion channel inhibitors and IL-12/23 inhibitors for the treatment of inflammatory diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Synta Pharmaceuticals Corp.

    Corporate Governance 
    Synta Pharmaceuticals Corp.’s ISS Governance QuickScore as of Mar 1, 2015 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Keith R. Gollust , 69
    Exec. Chairman, Chairman of Exec. Committee, Member of Audit Committee and Member of Compensation Committee
    N/AN/A
    Dr. Vojo Vukovic M.D., Ph.D., 48
    Chief Medical Officer and Sr. VP
    486.00K0.00
    Ms. Anne Clem Whitaker , 48
    Chief Exec. Officer, Pres and Director
    N/AN/A
    Dr. Lan Bo Chen Ph.D., 71
    Co-Founder
    N/AN/A
    Mr. Marc R. Schneebaum , 61
    Chief Financial Officer and Sr. VP
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders